Congestive Heart Failure Treatment Devices Market Anticipated To Grow Steadily, Supported By Demand Drivers And Key Industry Trends
What Is The Present Market Size Of The Congestive Heart Failure Treatment Devices Market, And At What Annual Growth Rate Is It Expanding?
The congestive heart failure treatment devices market size has grown strongly in recent years. It will grow from $21.07 billion in 2025 to $22.76 billion in 2026 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to rising prevalence of congestive heart failure, increasing incidence of cardiovascular diseases, growth in implantable cardiac device usage, expansion of specialized cardiac care facilities, improved survival rates of heart failure patients.
The congestive heart failure treatment devices market size is expected to see strong growth in the next few years. It will grow to $30.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to aging population with higher heart failure risk, increasing demand for minimally invasive cardiac therapies, growing focus on early intervention and disease management, expanding access to advanced heart failure treatment in emerging markets, rising adoption of long-term mechanical circulatory support devices. Major trends in the forecast period include rising adoption of advanced implantable heart failure devices, increasing use of ventricular assist devices in advanced chf, growing focus on reducing heart failure hospitalizations, expansion of device-based therapies for long-term heart support, increasing demand for continuous cardiac monitoring and management.
Claim Your Free Report Sample Today:
Which Major Drivers Are Strengthening Demand In The Congestive Heart Failure Treatment Devices Market?
The rise in the prevalence of cardiovascular disorders is expected to propel the growth of the congestive heart failure treatment devices market going forward. Cardiovascular disorders encompass a range of diseases affecting the heart and blood vessels, including coronary artery disease, hypertension, and heart failure, impacting blood circulation and overall heart health. The rise in the prevalence of cardiovascular disorders is primarily due to increasing rates of risk factors such as obesity, sedentary lifestyles, poor diets, and aging populations. Congestive heart failure treatment devices are crucial in managing cardiovascular disorders by regulating heart rhythms and improving heart function, significantly enhancing patient outcomes. For instance, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2023, cardiovascular disease claimed 919,032 lives, accounting for one in every three deaths. Coronary heart disease remained the most prevalent form of heart disease, and notably, about one in six deaths from cardiovascular diseases occurred among adults younger than 65 years. Therefore, the rise in the prevalence of cardiovascular disorders is driving the growth of the congestive heart failure (CHF) treatment devices market.
How Is The Congestive Heart Failure Treatment Devices Market Divided Across Its Major Segment Categories?
The congestive heart failure treatment devices market covered in this report is segmented –
1) By Product: Cardiac Pacemaker, Implantable Cardioverter Defibrillators (ICDs), Cardiac Resynchronization Therapy Devices (CRT), Counter Pulsation Devices, Ventricular Assist Devices (VADs)
2) By Application: Left Ventricular Assist Device (LVAD), Right Ventricular Assist Device (RVAD), Biventricular Assist Device (BIVAD)
3) By End-User: Hospitals And Clinic, Specialized Cardiovascular Disease Treatment Centers, Ambulatory Surgery Centers
Subsegments:
1) By Cardiac Pacemaker: Single Chamber Pacemaker, Dual Chamber Pacemaker, Biventricular Pacemaker
2) By Implantable Cardioverter Defibrillators (ICDs): Traditional ICDs, Subcutaneous ICDs, CRT-D (Cardiac Resynchronization Therapy Defibrillator)
3) By Cardiac Resynchronization Therapy Devices (CRT): CRT-P (Cardiac Resynchronization Therapy Pacemaker), CRT-D (Cardiac Resynchronization Therapy Defibrillator)
4) By Counter Pulsation Devices: Intra-Aortic Balloon Pumps (IABP), External Counterpulsation Devices (ECP)
5) By Ventricular Assist Devices (VADs): Left Ventricular Assist Devices (LVAD), Right Ventricular Assist Devices (RVAD), Biventricular Assist Devices (BiVAD)
Which Strategic Trends Are Likely To Impact Competitive Positioning In The Congestive Heart Failure Treatment Devices Market?
Major companies operating in the congestive heart failure treatment devices market are focusing on developing innovative solutions such as the implant-free atrial septostomy system to enhance hemodynamic relief, reduce procedural complexity, and offer less invasive treatment alternatives for heart failure patients. An implant-free atrial septostomy system refers to a minimally invasive device designed to create a controlled opening in the atrial septum without leaving a permanent implant, enabling improved left atrial pressure reduction and enhanced cardiac hemodynamics in heart failure patients. For instance, in January 2025, Alleviant Medical Inc., a US-based medical device company, received significant FDA milestones for its novel no-implant interatrial shunt device for treating heart failure. It offers a minimally invasive solution for heart failure by creating a precise shunt that reduces elevated pressure in the left atrium without leaving a permanent implant. This approach minimizes complications linked to implanted devices, promotes durable shunt patency, and improves symptoms, exercise capacity, and quality of life for chronic heart failure patients. Its purpose is to unload the heart, alleviate symptoms, and provide a safer, innovative treatment option for patients with limited alternatives.
Which Influential Players Dominate The Competitive Environment Of The Congestive Heart Failure Treatment Devices Market?
Major companies operating in the congestive heart failure treatment devices market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co KG, LivaNova PLC, Berlin Heart GmbH, Jarvik Heart Inc, ReliantHeart Inc, Abiomed Inc, Lepu Medical Technology Co Ltd, Magenta Medical Ltd, MicroPort Inc, EBR Systems Inc, Syncardia Systems LLC, Oscor Inc, OSYPKA Medical GmbH, Calon Cardio-Technology, CoreWave SA, Zoll Medical Corporation
Get Your In-Depth Congestive Heart Failure Treatment Devices Market Report Now:
Which Geographic Markets Are Contributing Most Significantly To The Progress Of The Congestive Heart Failure Treatment Devices Market?
North America was the largest region in the congestive heart failure treatment devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure treatment devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment